Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,517 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Regulatory
402 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Zoledronic Acid | US FDA | Paget Disease | Treatment of Paget’s disease of bone in men and women | approved | Apr 16, 2007 | openfda |
| Zongertinib | US FDA | Lung Non-Squamous Non-Small Cell Carcinoma | HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ] . This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. HERNEXEOS is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. ( 1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 )accelerated | approved | Aug 8, 2025 | openfda |
Data updated 2 days agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Erlotinib | 219 | 139 | 80 |
| Crizotinib | 175 | 86 | 89 |
| Gefitinib | 151 | 126 | 25 |
| Afatinib | 106 | 99 | 7 |
| Trastuzumab | 75 | 50 | 25 |
| Osimertinib | 53 | 39 | 14 |
| Cisplatin | 42 | 31 | 10 |
| Trametinib | 41 | 38 | 3 |
| Vemurafenib | 38 | 23 | 15 |
| Erdafitinib | 37 | 35 | 2 |
| Lapatinib | 36 | 24 | 12 |
| Olaparib | 36 | 34 | 2 |
| Cetuximab | 33 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 26 |
| 6 |
| Vismodegib | 29 | 5 | 24 |
| Pembrolizumab | 28 | 24 | 4 |
| Chemotherapy | 27 | 26 | 1 |
| Futibatinib | 27 | 25 | 2 |
| Gemcitabine | 27 | 21 | 5 |
| Infigratinib | 26 | 23 | 3 |
| Ceritinib | 25 | 20 | 5 |
| Everolimus | 25 | 21 | 4 |
| Selpercatinib | 25 | 19 | 6 |
| Dabrafenib | 23 | 22 | 1 |
| Trastuzumab Deruxtecan | 23 | 23 | 0 |
| Alectinib | 20 | 13 | 7 |
| Sorafenib | 20 | 17 | 3 |
| Carboplatin | 19 | 17 | 2 |
| Dactolisib | 19 | 11 | 8 |
| Selumetinib | 18 | 16 | 2 |
| Docetaxel | 17 | 11 | 6 |
| Neratinib | 17 | 17 | 0 |
| Paclitaxel | 17 | 10 | 6 |
| Trastuzumab Emtansine | 17 | 8 | 9 |
| Dasatinib | 16 | 15 | 1 |
| PI103 | 16 | 16 | 0 |
| Atezolizumab | 15 | 13 | 2 |
| Capmatinib | 15 | 13 | 1 |
| Dacomitinib | 14 | 13 | 1 |
| Lorlatinib | 14 | 11 | 3 |
| Palbociclib | 14 | 13 | 1 |
| Pemetrexed | 14 | 10 | 4 |
| Tepotinib | 14 | 14 | 0 |
| Cabozantinib | 13 | 12 | 1 |
| Larotrectinib | 13 | 12 | 1 |
| Pazopanib | 13 | 12 | 1 |
| Sotorasib | 13 | 13 | 0 |
| Entrectinib | 12 | 10 | 2 |
| Platinum Compound | 12 | 11 | 1 |
| Pertuzumab | 11 | 11 | 0 |
| Pictilisib | 11 | 11 | 0 |
| Sirolimus | 11 | 11 | 0 |
| Sunitinib | 11 | 8 | 2 |
| Durvalumab | 10 | 9 | 1 |
| Immune Checkpoint Inhibitor | 10 | 8 | 1 |
| Nivolumab | 10 | 8 | 2 |
| Brigatinib | 9 | 8 | 1 |
| Fluorouracil | 9 | 8 | 1 |
| PD173074 | 9 | 9 | 0 |
| Talazoparib | 9 | 9 | 0 |
| Bevacizumab | 8 | 7 | 1 |
| Enzalutamide | 7 | 7 | 0 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 7 | 5 | 2 |
| Sunvozertinib | 7 | 7 | 0 |
| Vandetanib | 7 | 6 | 1 |
| ALK Inhibitor TAE684 | 6 | 4 | 2 |
| Capecitabine | 6 | 5 | 1 |
| Fexagratinib | 6 | 6 | 0 |
| Foretinib | 6 | 5 | 1 |
| Imatinib | 6 | 6 | 0 |
| Panitumumab | 6 | 4 | 2 |
| Taselisib | 6 | 5 | 1 |
| Alpelisib | 5 | 4 | 1 |
| Amivantamab | 5 | 5 | 0 |
| Dovitinib | 5 | 5 | 0 |
| Imatinib Mesylate | 5 | 5 | 0 |
| MEK Inhibitor CI-1040 | 5 | 5 | 0 |
| Radiation Therapy | 5 | 3 | 2 |
| Rociletinib | 5 | 4 | 1 |
| Rucaparib | 5 | 5 | 0 |
| Sapanisertib | 5 | 5 | 0 |
| SU11274 | 5 | 5 | 0 |
| Abemaciclib | 4 | 4 | 0 |
| Akt Inhibitor MK2206 | 4 | 4 | 0 |
| Icotinib | 4 | 3 | 1 |
| Ipilimumab/Nivolumab Regimen | 4 | 4 | 0 |
| MTOR Inhibitor | 4 | 4 | 0 |
| Niraparib | 4 | 4 | 0 |
| PD1 Inhibitor | 4 | 3 | 1 |
| PI3Ka/Di | 4 | 3 | 1 |
| Ponatinib | 4 | 4 | 0 |
| Pralsetinib | 4 | 1 | 3 |
| Repotrectinib | 4 | 4 | 0 |
| Ruxolitinib | 4 | 4 | 0 |
| Vistusertib | 4 | 4 | 0 |
| Alisertib | 3 | 3 | 0 |
| Alvespimycin | 3 | 3 | 0 |
| Anti-PD1 Monoclonal Antibody | 3 | 2 | 1 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| ARS-1620 | 3 | 3 | 0 |
| Avelumab | 3 | 2 | 1 |
| AZD-4547 | 3 | 3 | 0 |
| Capivasertib | 3 | 3 | 0 |
| Cisplatin/Pembrolizumab/Pemetrexed Regimen | 3 | 0 | 3 |
| Dabrafenib/Trametinib Regimen | 3 | 3 | 0 |
| Deguelin | 3 | 3 | 0 |
| EAP Protocol | 3 | 3 | 0 |
| Ensartinib | 3 | 3 | 0 |
| Etoposide | 3 | 3 | 0 |
| Fulvestrant | 3 | 2 | 1 |
| Irinotecan | 3 | 3 | 0 |
| Ivosidenib | 3 | 3 | 0 |
| Lazertinib | 3 | 3 | 0 |
| Lenvatinib | 3 | 2 | 1 |
| Mitomycin | 3 | 2 | 1 |
| Oxaliplatin | 3 | 1 | 2 |
| PI-103 | 3 | 3 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 3 | 3 | 0 |
| Poziotinib | 3 | 3 | 0 |
| Ramucirumab | 3 | 2 | 1 |
| Sonidegib | 3 | 2 | 1 |
| Temsirolimus | 3 | 3 | 0 |
| Vinorelbine | 3 | 3 | 0 |
| Zongertinib | 3 | 3 | 0 |
| Adagrasib | 2 | 2 | 0 |
| Adjuvant Chemotherapy | 2 | 2 | 0 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | 2 | 2 | 0 |
| Anti-PD-L1 Monoclonal Antibody | 2 | 1 | 1 |
| Aspirin | 2 | 2 | 0 |
| Aumolertinib | 2 | 1 | 1 |
| Axitinib | 2 | 0 | 2 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 2 | 2 | 0 |
| Camonsertib | 2 | 2 | 0 |
| Canertinib | 2 | 2 | 0 |
| Carboplatin/Paclitaxel Regimen | 2 | 2 | 0 |
| Carboplatin/Pemetrexed Regimen | 2 | 2 | 0 |
| Checkpoint Kinase Inhibitor AZD7762 | 2 | 2 | 0 |
| Derazantinib | 2 | 2 | 0 |
| Dinaciclib | 2 | 2 | 0 |
| Doxorubicin | 2 | 1 | 1 |
| Durvalumab/Tremelimumab Regimen | 2 | 2 | 0 |
| Firmonertinib | 2 | 2 | 0 |
| Imlunestrant Regimen | 2 | 2 | 0 |
| Immunotherapy | 2 | 2 | 0 |
| Ipilimumab | 2 | 2 | 0 |
| Irbesartan | 2 | 2 | 0 |
| JQ1 | 2 | 2 | 0 |
| JSI-124 | 2 | 2 | 0 |
| KRAS G12D Inhibitor HRS-4642 | 2 | 2 | 0 |
| Leucovorin | 2 | 2 | 0 |
| Lunresertib | 2 | 2 | 0 |
| Metformin | 2 | 2 | 0 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 2 | 1 | 1 |
| Mobocertinib | 2 | 2 | 0 |
| Motesanib | 2 | 0 | 2 |
| Nab-paclitaxel | 2 | 1 | 1 |
| NSC84167 | 2 | 2 | 0 |
| Palbociclib Regimen | 2 | 2 | 0 |
| Panobinostat | 2 | 2 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 2 | 2 | 0 |
| Pemigatinib | 2 | 1 | 1 |
| Prexasertib | 2 | 2 | 0 |
| Regorafenib Anhydrous | 2 | 2 | 0 |
| Retaspimycin Hydrochloride | 2 | 2 | 0 |
| Ribociclib | 2 | 2 | 0 |
| Rovalpituzumab Tesirine | 2 | 2 | 0 |
| Sacituzumab Govitecan | 2 | 0 | 2 |
| Savolitinib | 2 | 1 | 1 |
| Setidegrasib | 2 | 2 | 0 |
| Sevabertinib | 2 | 2 | 0 |
| Sintilimab | 2 | 2 | 0 |
| Sulindac | 2 | 2 | 0 |
| Taletrectinib | 2 | 2 | 0 |
| Tanespimycin | 2 | 2 | 0 |
| Tipifarnib | 2 | 2 | 0 |
| Tremelimumab | 2 | 2 | 0 |
| Zenocutuzumab-zbco | 2 | 2 | 0 |
| Zolbetuximab | 2 | 2 | 0 |
| 2,4-pyrimidinediamine | 1 | 1 | 0 |
| 2-Deoxy-D-glucose | 1 | 1 | 0 |
| 7-Ethyl-10-Hydroxycamptothecin | 1 | 1 | 0 |
| 9F7-F11 | 1 | 1 | 0 |
| A66 | 1 | 1 | 0 |
| Abemaciclib Regimen | 1 | 1 | 0 |
| Abexinostat | 1 | 1 | 0 |
| Abiraterone | 1 | 1 | 0 |
| Adavosertib | 1 | 1 | 0 |
| Adebrelimab | 1 | 1 | 0 |
| Ado-trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| AMG511 | 1 | 1 | 0 |
| Anti-CTLA-4 Monoclonal Antibody | 1 | 1 | 0 |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | 1 | 1 | 0 |
| Anti-PDL1 Therapy | 1 | 1 | 0 |
| Anti-TIM-3 Monoclonal Antibody | 1 | 1 | 0 |
| Apitolisib | 1 | 1 | 0 |
| Aromatase Inhibitor | 1 | 1 | 0 |
| Arsenic Trioxide | 1 | 1 | 0 |
| ATR Inhibitor | 1 | 1 | 0 |
| Avutometinib And Defactinib | 1 | 1 | 0 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | 1 | 1 | 0 |
| AZD3463 | 1 | 0 | 1 |
| Barasertib | 1 | 1 | 0 |
| Bazedoxifene | 1 | 1 | 0 |
| Befotertinib | 1 | 1 | 0 |
| Bicalutamide | 1 | 0 | 1 |
| Bimiralisib | 1 | 1 | 0 |
| Binimetinib | 1 | 1 | 0 |
| Birabresib | 1 | 1 | 0 |
| BMVC-8C3O | 1 | 1 | 0 |
| Bortezomib | 1 | 1 | 0 |
| Bosutinib | 1 | 1 | 0 |
| C646 | 1 | 1 | 0 |
| Camrelizumab | 1 | 1 | 0 |
| CAPOX Regimen | 1 | 1 | 0 |
| Carboplatin OR Cisplatin | 1 | 0 | 1 |
| C-DIM 12 | 1 | 0 | 1 |
| Celecoxib | 1 | 1 | 0 |
| CH6953755 | 1 | 1 | 0 |
| Chemoimmunotherapy | 1 | 0 | 1 |
| Chemoradiotherapy | 1 | 0 | 1 |
| Copanlisib | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Dacomitinib | 1 | 1 | 0 |
| Datopotamab Deruxtecan | 1 | 1 | 0 |
| Datopotamab Deruxtecan Regimen | 1 | 1 | 0 |
| Divarasib | 1 | 1 | 0 |
| Dostarlimab | 1 | 1 | 0 |
| DS-6501b | 1 | 1 | 0 |
| Durvalumab Regimen | 1 | 1 | 0 |
| EGFR Tyrosine Kinase Inhibitor Therapy | 1 | 1 | 0 |
| Enzastaurin | 1 | 1 | 0 |
| Eribulin | 1 | 1 | 0 |
| Erlotinib Hydrochloride | 1 | 1 | 0 |
| Fadraciclib | 1 | 1 | 0 |
| Fasudil | 1 | 1 | 0 |
| FGFR4 Inhibitor H3B-6527 | 1 | 1 | 0 |
| FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 1 | 1 | 0 |
| Fisogatinib | 1 | 1 | 0 |
| FOLFOX-6 Regimen | 1 | 1 | 0 |
| Ganetespib | 1 | 1 | 0 |
| Ganitumab | 1 | 1 | 0 |
| G-Quadruplex Stabilizer BMVC | 1 | 1 | 0 |
| Ibrutinib | 1 | 1 | 0 |
| Ibuprofen | 1 | 1 | 0 |
| ICX-101 | 1 | 1 | 0 |
| Idelalisib | 1 | 1 | 0 |
| Iodine I-131 | 1 | 0 | 1 |
| JAK2 Inhibitor AZD1480 | 1 | 1 | 0 |
| JNJ38877605 | 1 | 0 | 1 |
| JW55 | 1 | 1 | 0 |
| Lestaurtinib | 1 | 1 | 0 |
| Linsitinib | 1 | 1 | 0 |
| Luminespib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| MEK Inhibitor RO4987655 | 1 | 0 | 1 |
| Mirdametinib | 1 | 1 | 0 |
| Molibresib | 1 | 1 | 0 |
| MTOR Kinase Inhibitor AZD8055 | 1 | 1 | 0 |
| MUC1-targeted Peptide GO-203-2C | 1 | 0 | 1 |
| Naquotinib | 1 | 0 | 1 |
| Nedaplatin | 1 | 0 | 1 |
| Nilotinib | 1 | 1 | 0 |
| Nimotuzumab | 1 | 1 | 0 |
| Nintedanib | 1 | 1 | 0 |
| NVP-AST487 | 1 | 1 | 0 |
| Onartuzumab | 1 | 1 | 0 |
| Onatasertib | 1 | 1 | 0 |
| Osimertinib Mesylate | 1 | 1 | 0 |
| Paclitaxel Liposome | 1 | 1 | 0 |
| Palliative Radiation Therapy | 1 | 0 | 1 |
| Pan-AKT Kinase Inhibitor GSK690693 | 1 | 1 | 0 |
| Patritumab | 1 | 1 | 0 |
| PD-1 Ligand Inhibitor | 1 | 1 | 0 |
| PD-L1 Inhibitor | 1 | 1 | 0 |
| Pembrolizumab/Pemetrexed Regimen | 1 | 1 | 0 |
| Pertuzumab/Trastuzumab Regimen | 1 | 0 | 1 |
| PHA-665752 | 1 | 0 | 1 |
| PI3K/BET Inhibitor LY294002 | 1 | 1 | 0 |
| Pilaralisib | 1 | 1 | 0 |
| Platinum Doublet | 1 | 0 | 1 |
| Porcupine Inhibitor WNT974 | 1 | 1 | 0 |
| PSI | 1 | 1 | 0 |
| Pyrotinib | 1 | 1 | 0 |
| R3Mab | 1 | 0 | 1 |
| Radioactive Iodine | 1 | 1 | 0 |
| Raltitrexed | 1 | 0 | 1 |
| Refametinib | 1 | 1 | 0 |
| Regorafenib | 1 | 1 | 0 |
| Rilotumumab | 1 | 1 | 0 |
| RMC-4550 | 1 | 1 | 0 |
| Roflumilast | 1 | 1 | 0 |
| Salirasib | 1 | 1 | 0 |
| SCH772984 | 1 | 1 | 0 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | 1 | 1 | 0 |
| SHP2 Inhibitor | 1 | 1 | 0 |
| Stattic | 1 | 1 | 0 |
| Staurosporine | 1 | 1 | 0 |
| TAK-788 | 1 | 1 | 0 |
| Tarextumab | 1 | 1 | 0 |
| Tarloxotinib | 1 | 1 | 0 |
| Taxane Compound | 1 | 1 | 0 |
| Temozolomide | 1 | 1 | 0 |
| Teprotumumab | 1 | 1 | 0 |
| Tgx 221 | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Tislelizumab | 1 | 1 | 0 |
| Tizaterkib | 1 | 1 | 0 |
| Toripalimab | 1 | 1 | 0 |
| Tozasertib | 1 | 1 | 0 |
| Tretinoin | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor SU5402 | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| Volasertib | 1 | 1 | 0 |
| Vorinostat | 1 | 1 | 0 |
| WHI-P154 | 1 | 1 | 0 |
| WRN Inhibitor HRO761 | 1 | 1 | 0 |
| WRN Inhibitor RO7589831 | 1 | 1 | 0 |
| WZ4002 | 1 | 0 | 1 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.